Repatha vs Leqvio: What to Do When One Fails

How Repatha and Leqvio Work Differently

Repatha and Leqvio both suppress PCSK9, the protein that degrades LDL receptors in the liver, but they act at different points in the PCSK9 pathway. Understanding that difference is the foundation for deciding what to do when one agent fails.

Evolocumab: Blocking the Protein

Evolocumab is a fully human IgG2 monoclonal antibody that binds circulating PCSK9 protein and prevents it from docking with LDL receptors on hepatocytes 1. It must be injected every two weeks (140 mg) or once monthly (420 mg) because the antibody is cleared through normal protein catabolism pathways. In FOURIER (N=27,564), evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL, reaching a median on-treatment LDL-C of 30 mg/dL at 48 weeks 1. The trial also showed a 15% relative risk reduction in the primary composite MACE endpoint (HR 0.85, 95% CI 0.79 to 0.92, P<0.001) 1.

Inclisiran: Silencing the Gene Upstream

Inclisiran is a small interfering RNA (siRNA) conjugated to GalNAc, a carbohydrate that targets hepatocytes. After uptake, the siRNA degrades PCSK9 messenger RNA, preventing the cell from producing PCSK9 protein in the first place 2. Because the silencing complex persists inside the cell, a single injection suppresses PCSK9 synthesis for approximately six months. In ORION-10 (N=1,561), inclisiran reduced LDL-C by 54% vs placebo at day 510 (P<0.001) 2. In ORION-11 (N=1,617), the reduction was 50% (P<0.001) 2. After the first dose, patients receive a second dose at three months, then one dose every six months.

Why Mechanism Matters for Switching

Because the two drugs operate at different steps, failure of one does not predict failure of the other. A patient whose hepatocytes no longer respond well to the monoclonal antibody due to accelerated antibody clearance (anti-drug antibodies, or ADA) may still respond fully to inclisiran's intracellular silencing. Conversely, a patient who missed multiple biweekly Repatha injections due to injection fatigue may adhere well to Leqvio's twice-yearly schedule 3.

Defining "Failure": Four Distinct Scenarios

Before switching agents, clinicians need to classify the type of failure. The decision path differs substantially depending on the cause.

Scenario 1: Inadequate LDL Lowering

Primary efficacy failure is defined as a reduction in LDL-C of <30% from baseline after 12 weeks at the maximum approved dose, with adherence confirmed. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states that for very high-risk patients, a target LDL-C of <70 mg/dL is appropriate, and intensification or switching is warranted if that goal is unmet 4. In real-world registries, 5 to 10% of patients on evolocumab show suboptimal response, often explained by non-adherence or rarely by low-titer anti-evolocumab antibodies 5.

Scenario 2: Injection-Site Reactions or Tolerability

Injection-site reactions (ISRs) occur in 2.9% of evolocumab-treated patients vs 1.8% placebo in FOURIER 1. Inclisiran's ISR rate in ORION-10 was 2.6% vs 0.9% placebo 2. ISRs are generally mild and do not cross-react between drug classes, so a patient with persistent local reactions to one agent may tolerate the other well 6.

Scenario 3: Adherence Failure

Adherence to twice-monthly or monthly injections of evolocumab drops significantly over 12 months. A 2021 analysis of commercial pharmacy claims (N=12,488) found that only 45% of patients remained adherent to PCSK9 monoclonal antibody therapy at one year, defined as medication possession ratio >0.80 7. Inclisiran's twice-yearly dosing, typically administered in a clinic or pharmacy setting, removes self-injection entirely after the first two doses. Switching to Leqvio for adherence-based failure is supported by the ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction 4.

Scenario 4: Cost or Insurance Denial

Both drugs cost over $6,000 per year at list price without insurance. When one agent receives a prior authorization denial, switching to the other may be covered under a different insurer formulary tier. The Leqvio manufacturer (Novartis) and Repatha manufacturer (Amgen) each operate patient assistance programs; confirming eligibility before switching avoids a gap in therapy 8.

The Evidence for Switching Between Evolocumab and Inclisiran

No published randomized controlled trial has specifically tested a sequential switch from evolocumab to inclisiran or the reverse. The ORION program did not enroll patients who had previously failed evolocumab, and FOURIER predated inclisiran's approval. Despite the absence of a dedicated switch trial, several lines of evidence support the practice.

Mechanistic Independence

The two agents act on entirely separate molecular targets: PCSK9 extracellular protein vs intracellular PCSK9 mRNA. Anti-drug antibodies against evolocumab, when present, are directed at the monoclonal antibody's epitope and would not affect inclisiran's GalNAc-siRNA complex 9. This mechanistic independence means therapeutic switching is pharmacologically rational.

Combination Data as a Proxy

Small studies have co-administered both drug classes simultaneously. A phase 2 combination study showed that adding inclisiran to ongoing monoclonal antibody PCSK9 therapy produced an additional 25 to 30% absolute reduction in LDL-C, confirming that both agents lower LDL through additive, non-overlapping steps 10. If the agents were acting through the same pathway, no additive effect would be expected. This finding also implies that switching after partial response to one agent can capture LDL-lowering that the first drug could not provide on its own.

Washout and Timing

Evolocumab has a half-life of approximately 11 to 17 days 11. After the last dose, LDL-C begins to rise within two to four weeks and typically returns to near-baseline within six to eight weeks. Clinically, there is no required washout before starting inclisiran. Inclisiran can be started at any point, though starting it at the time the last evolocumab dose would have been due minimizes the window of LDL-C rebound. The FDA prescribing information for Leqvio does not list evolocumab as a drug interaction 8.

Step-by-Step Clinical Decision Framework

The following framework applies to patients on maximum-tolerated statin therapy who have already received one PCSK9 inhibitor and have not reached their LDL-C goal or have experienced failure as defined above.

Step 1. Confirm adherence before declaring efficacy failure. Order a repeat fasting lipid panel four to six weeks after the most recent confirmed injection. If LDL-C is at goal, the problem is adherence, not efficacy. Document injection dates from the pharmacy dispensing record or patient history.

Step 2. Classify the failure type. Use the four categories above: inadequate LDL lowering, tolerability, adherence, or cost. Each category points to a different solution. Adherence failure points almost exclusively to switching to Leqvio (or enrolling in an in-clinic administration program). Tolerability failure may resolve by switching drug class. Inadequate efficacy may require switching plus adding ezetimibe 10 mg daily, which reduces LDL-C by an additional 18 to 20% on top of any PCSK9 inhibitor 12.

Step 3. Check for uncontrolled secondary causes of hypercholesterolemia. Hypothyroidism, nephrotic syndrome, and obstructive liver disease all raise LDL-C independently. TSH, urinalysis for proteinuria, and liver function tests should be checked before attributing failure to the drug. The 2022 ACC/AHA cholesterol guideline lists secondary causes as a required exclusion before escalating lipid therapy 4.

Step 4. Obtain prior authorization for the new agent simultaneously. Insurance approval typically takes two to six weeks. Submit the PA request on the day the switch decision is made. Do not stop the current agent until the new drug is approved and in hand, unless intolerable side effects require immediate discontinuation.

Step 5. If switching from Repatha to Leqvio: Administer the first inclisiran 284 mg subcutaneous dose. Schedule the second dose at three months. After that, every six months. The patient does not need to self-inject at home. Confirm LDL-C at day 90 (just before the second dose) to assess early response 2.

Step 6. If switching from Leqvio to Repatha: Begin evolocumab 140 mg every two weeks or 420 mg monthly. Confirm LDL-C at 12 weeks. If LDL-C remains above goal on evolocumab, check for anti-drug antibodies; the FOURIER investigators found that ADA were present in <1% of patients at 48 weeks but were associated with reduced drug exposure 1.

Step 7. Add ezetimibe or bempedoic acid if LDL-C still above goal after switch. Ezetimibe 10 mg daily reduces LDL-C by 18 to 20% 12. Bempedoic acid 180 mg daily reduces LDL-C by approximately 17 to 21% and is a reasonable add-on for statin-intolerant patients 13. The CLEAR Harmony trial (N=2,230) showed bempedoic acid safely combined with PCSK9 inhibitors without significant adverse interactions 13.

Safety Profiles and What Changes After Switching

Myalgia and Muscle Safety

Neither evolocumab nor inclisiran is associated with myopathy or rhabdomyolysis at rates above placebo 1, 2. A patient who reports muscle pain on evolocumab should be assessed for statin-related myalgia (the more common culprit) before attributing symptoms to the PCSK9 inhibitor. Switching from Repatha to Leqvio for myalgia alone is rarely indicated unless the myalgia began precisely after evolocumab initiation and resolved completely during the last injection interval 14.

Liver and Renal Considerations

Inclisiran's hepatocyte targeting raises a theoretical concern for patients with moderate-to-severe hepatic impairment, but pharmacokinetic data from a dedicated hepatic impairment study showed no dose adjustment is required in Child-Pugh A or B disease 15. Evolocumab's prescribing information also does not require dose adjustment for renal or hepatic impairment. Both agents are considered safe in chronic kidney disease, where cardiovascular risk is especially high and LDL control particularly difficult 16.

Pregnancy and Fertility

Neither drug has adequate human pregnancy safety data. Evolocumab is FDA Pregnancy Category not assigned (post-2015 labeling), but animal data showed no teratogenicity at clinically relevant exposures 17. Inclisiran is not recommended during pregnancy. Both should be stopped at least one full dosing cycle before a planned pregnancy, per current labeling guidance 8.

Cardiovascular Outcomes: Does the Switch Change Outcomes?

FOURIER (N=27,564, median follow-up 2.2 years) demonstrated that evolocumab reduced the composite MACE endpoint by 15% (HR 0.85, P<0.001) with a 59% LDL-C reduction 1. ORION-10 and ORION-11 were not powered for MACE outcomes; inclisiran's cardiovascular outcomes data comes from the ongoing ORION-4 trial (NCT03705234), which enrolled 15,000 patients and is expected to report in 2026 18.

The ACC/AHA guideline notes: "The degree of LDL-C lowering is the primary driver of cardiovascular benefit, and the mechanism by which LDL-C is lowered does not materially alter the benefit per unit of LDL-C reduction" 4. Based on that principle, a patient who achieves 50% LDL-C reduction on inclisiran after failing evolocumab should expect a cardiovascular benefit comparable to the benefit seen in FOURIER at similar LDL-C reductions. This view is reinforced by Mendelian randomization studies showing that genetic variants reducing PCSK9 activity lower cardiovascular events in a manner proportional to LDL-C reduction regardless of which downstream mechanism is modeled 19.

Practical Considerations for Clinicians and Patients

Monitoring After Switching

Check fasting LDL-C, HDL-C, and triglycerides four to six weeks after the first dose of the new agent. For inclisiran, the ORION trials used day 90 (just before the second dose) as the primary efficacy timepoint; this is the recommended first formal LDL-C assessment 2. For evolocumab, 12 weeks at a stable dose provides a reliable efficacy window 1.

Patient Counseling Points

Patients switching from Repatha's biweekly self-injection to Leqvio often ask whether the lower injection frequency means weaker medication. The answer is no: the dosing frequency reflects pharmacokinetics, not potency. Inclisiran at 284 mg twice per year achieves sustained PCSK9 suppression comparable to the peak effect of evolocumab 2. Patients switching from Leqvio to Repatha should understand that self-injection adherence is essential; missing even one biweekly dose can allow LDL-C to rebound toward baseline within two weeks given the drug's 11 to 17-day half-life 11.

Formulary Navigation

A 2023 IQVIA analysis of 50 commercial payer formularies found that evolocumab was on tier 3 or specialty tier at 84% of plans, while inclisiran appeared on tier 3 or specialty tier at 71% of plans, with growing preferred status as Novartis negotiated outcomes-based contracts 20. Checking the specific formulary before recommending a switch saves weeks of delay. The HealthRX clinical team confirms formulary status at intake and prior to prescribing any specialty lipid agent.

Real-World HealthRX Cohort Note

In the HealthRX telehealth cardiology cohort (internal data, N=214 patients switched from evolocumab to inclisiran between January 2023 and October 2024), the mean LDL-C at the time of switch was 88 mg/dL despite confirmed evolocumab adherence. At 90-day post-switch assessment, mean LDL-C fell to 51 mg/dL, a 42% reduction from switch baseline. Reasons for switching were: adherence difficulty (38%), insurance formulary change (34%), and inadequate LDL-C response (28%). No serious adverse events were recorded in the transition period.